GSK-Vir COVID-19 drug effective vs. Omicron - data

EPA-EFE/STRINGER

GlaxoSmithKline plc confirmed on Tuesday that its COVID-19 therapy jointly developed with Vir Biotechnology is effective against the Omicron coronavirus mutation.

"Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2 variants of concern and interest to date, including Omicron, as well as the still prevalent and highly contagious Delta variant," Vir CEO George Scangos noted in a statement that announced the preliminary results.

Sotrovimab is widely used for treating COVID-19 patients in the United States and several other countries worldwide.

Baha Breaking News (BBN) / ND